The artificial pancreas: two alternative approaches to achieve a fully closed-loop system with optimal glucose control.

Autor: Åm MK; Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Postboks 8900, 7491, Trondheim, Norway. marte.k.am@ntnu.no., Teigen IA; Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Postboks 8900, 7491, Trondheim, Norway.; Cancer Clinic, St. Olav's Hospital, Trondheim University Hospital, Trondheim, Norway., Riaz M; Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Postboks 8900, 7491, Trondheim, Norway.; Department of Endocrinology, St. Olav's Hospital, Trondheim University Hospital, Trondheim, Norway., Fougner AL; Department of Engineering Cybernetics, Faculty of Information Technology and Electrical Engineering, Norwegian University of Science and Technology, Trondheim, Norway., Christiansen SC; Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Postboks 8900, 7491, Trondheim, Norway.; Department of Endocrinology, St. Olav's Hospital, Trondheim University Hospital, Trondheim, Norway., Carlsen SM; Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Postboks 8900, 7491, Trondheim, Norway.; Department of Endocrinology, St. Olav's Hospital, Trondheim University Hospital, Trondheim, Norway.

Publikováno v: Journal of endocrinological investigation [J Endocrinol Invest] 2024 Mar; Vol. 47 (3), pp. 513-521. Date of Electronic Publication: 2023 Sep 15.

Vasodilatory effects of glucagon: A possible new approach to enhanced subcutaneous insulin absorption in artificial pancreas devices.

Autor: Teigen IA; Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway., Riaz M; Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway.; Department of Endocrinology, St. Olav's Hospital, Trondheim University Hospital, Trondheim, Norway., Åm MK; Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway., Christiansen SC; Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway.; Department of Endocrinology, St. Olav's Hospital, Trondheim University Hospital, Trondheim, Norway., Carlsen SM; Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway.; Department of Endocrinology, St. Olav's Hospital, Trondheim University Hospital, Trondheim, Norway.

Publikováno v: Frontiers in bioengineering and biotechnology [Front Bioeng Biotechnol] 2022 Sep 21; Vol. 10, pp. 986858. Date of Electronic Publication: 2022 Sep 21 (Print Publication: 2022).

Pharmacokinetics of Intraperitoneally Delivered Glucagon in Pigs: A Hypothesis of First Pass Metabolism.

Autor: Teigen IA; Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology (NTNU), 7491, Trondheim, Norway. ingrid.a.teigen@ntnu.no., Åm MK; Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology (NTNU), 7491, Trondheim, Norway., Carlsen SM; Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology (NTNU), 7491, Trondheim, Norway.; Department of Endocrinology, St. Olav's Hospital, Trondheim University Hospital, 7006, Trondheim, Norway., Christiansen SC; Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology (NTNU), 7491, Trondheim, Norway.; Department of Endocrinology, St. Olav's Hospital, Trondheim University Hospital, 7006, Trondheim, Norway.

Publikováno v: European journal of drug metabolism and pharmacokinetics [Eur J Drug Metab Pharmacokinet] 2021 Jul; Vol. 46 (4), pp. 505-511. Date of Electronic Publication: 2021 Jun 07.

A patient with maculopapular rash and lichenoid skin damage caused by ponatinib.

Autor: Teigen IA; Department of Pharmacology, Haukeland University Hospital, N-5021 Bergen, Norway., Sæle AKM; Department of Pathology, Haukeland University Hospital, N-5021 Bergen, Norway.; Institute of Medical Science, Medical Faculty, University of Bergen, N-5021 Bergen, Norway., Reikvam H; Institute of Clinical Science, Medical Faculty, University of Bergen, N-5021 Bergen, Norway.; Section of Hematology Department of Medicine, Haukeland University Hospital, N-5021 Bergen, Norway.

Publikováno v: The Journal of international medical research [J Int Med Res] 2020 Apr; Vol. 48 (4), pp. 300060520903660.

T.T. Serkland and colleagues respond.

Autor: Serkland TT, Pahr T, Teigen IA, Berg JA

Publikováno v: Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke [Tidsskr Nor Laegeforen] 2019 Nov 04; Vol. 139 (16). Date of Electronic Publication: 2019 Nov 04 (Print Publication: 2019).